Living with Laron syndrome can be challenging, especially when affected individuals cannot accept their short stature. It leads to low self-confidence and struggles in social and emotional well-being. About 300 to 500 people globally are diagnosed with this rare condition. It is time to raise awareness about treatment and medical care costs in India.
Replacement Therapy with Recombinant Human IGF-1 (rhIGF-1) is the only treatment for Laron syndrome. This therapy is done substantially twice a day through injection to reduce adiposity and improve linear growth in patients. Growth hormone therapy is ineffective in Laron Syndrome due to receptor insensitivity. Recombinant human IGF-1 (rhIGF-1) is the only effective treatment to improve linear growth and metabolic outcomes.
Doctors usually recommend prescribing a low-fat, high-protein diet to enhance IGF-1 response. Maintaining a diet while treating this rare genetic disease can reduce the risk of obesity in future.
Laron syndrome treatment involves two injections of rhIGF-1 and is tailored based on the child’s weight. For a child weighing 20 kg, the treatment cost is estimated at over Rs. 15 lakhs. While currently limited in availability, efforts are ongoing to improve access to this specialised therapy in India.
Here are some benefits of replacement therapy.
However, this replacement therapy also has some health risks, including:
In case Laron syndrome is left untreated, it can lead to life-threatening complications, including heart disease, cancer and diabetes. Early diagnosis and proper treatment can manage the symptoms of the affected individual. However, patients can strategise to manage this rare condition through:
Laron syndrome causes short stature from childhood due to growth hormone deficiency. The only treatment option is the administration of regular recombinant human IGF-1 replacement therapy via injection twice a day from early childhood. This treatment with high doses of daily therapy requires a huge cost for a single injection, which is inaccessible for the majority of patients.